News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Launch of trial of 'master switch' drug to treat several cancer types
Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The early-stage Phase I clinical trial of up to 40 patients will be carried out by the ICR, and The Royal Marsden Hospital.
Key driver of aggressive prostate cancer found
A key driver for aggressive forms of prostate cancer has been uncovered by scientists at The Institute of Cancer Research, London.
'Virtual experiments' aid scientists to find missing cancer targets
Scientists have identified 46 previously overlooked but potentially ‘druggable’ cancer targets, using a powerful new online approach that allows researchers to carry out ‘virtual experiments’ to quickly prioritise which are the best targets for drug discovery.
New partnership model needed to explore kinases for cancer treatments
International leaders in drug discovery have warned that a huge reservoir of potential targets for cancer treatment will remain unexplored unless public funders, charities and pharmaceutical companies come together in a new model of large-scale partnership.
Bowel cancer gene discovery cracks mystery of families with a strong history of the disease
Scientists have discovered that two gene faults increase the risk of bowel cancer in families with a strong history of developing the disease, who, until now, had no explanation as to why their risk was greater.
Scientists discover intriguing new gene link to breast and ovarian cancer
A team of researchers led from the ICR, have found that mutations in a gene called PPM1D are linked to an increased risk of breast and ovarian cancer – through what may be a new mechanism of cancer development.
Prostate cancer drug benefits earlier-stage disease
Prostate cancer drug benefits earlier-stage disease
The ICR welcomes £100m investment in high-tech genome profiling for cancer patients.
The ICR welcomes £100m Government investment in high-tech genome profiling for cancer patients.
Fewer, bigger doses of radiotherapy benefit breast cancer patients
Women diagnosed with breast cancer can benefit from receiving fewer but higher doses of radiotherapy than is the international standard, according to long-term follow-up data of a major UK-wide trial led by the ICR.
Kidney cancer genetic risk discovery
Scientists at the ICR have found a new genetic variation which increases a person’s risk of developing the most common type of kidney cancer.
The ICR and Royal Marsden open groundbreaking facility bringing smart trials to the NHS
Scientists will monitor whether new-generation cancer drugs are successfully hitting their targets by simply plucking samples from patients’ eyebrows following the opening of a new world-class research facility at The Royal Marsden and its academic research partner, The Institute of Cancer Research, London.
Professor Paul Workman to join Innovation Debate 2012
Professor Paul Workman, Deputy Chief Executive and head of cancer therapeutics at The Institute of Cancer Research, London, will join the distinguished panel of world-leading experts and chairman Professor Jim Al-Khalili for The Innovation Debate 2012, taking place on 20th November at 4pm at the Royal Society in London and webcast live.
